A review of clonazepam use in neurology

Neurologist

Volumn 3, Issue 2, 1997, Pages 120-127

  Khouzam, Hani Raoul ^a,b,c   Highet, Vicki Sue ^a,d  

^a Manchester VA Medical Center   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Clonazepam; Dosing; Movement disorders; Neuropathic pain; Nystagmus induced oscillopsia; Pharmacology; Seizure disorders; Side effects; Sleep associated disorders

Indexed keywords

EID: 1242348631     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00127893-199703000-00006     Document Type: Review

References (63)

1. Browne TR. Clonazepam. A review of a new anticonvulsant drug. Arch Neurol 1976;33:326-32.
2. Browne TR. Clonazepam. N Engl J Med 1978;299:812-6.
3. Biary N, Koller W. Kinetic predominant essential tremor: Successful treatment with clonazepam. Neurology 1987;34:471-4.
4. Thompson C, Lang A, Parkes JD, Marsden CD. A double-blind trial of clonazepam in benign essential tremor. Clin Neuropharmacol 1984;7:83-8.
5. Pritchett, DB, Sontheimer H, Shivers B, Yner S, Kettennam H, Scofield PR, et al. Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology. Nature 1989;13:582-5.
6. Hyman SE, Arana GW, Rosenbaum JF, editors. Handbook of psychiatric drug therapy. Boston: Little, Brown, and Company, 1995.
7. Hales RE, Yudofsky SC, Talbott JA, editors. Textbook of psychiatry. 2nd ed. Washington, DC: The American Psychiatric Press, 1994:30-1.
8. Kaplan SA, Alexander K, Jack ML, Puglisi CV, DeSilva J, Lee TL, et al. Pharmacokinetic profiles of clonazepam in dog and humans and of flunitrazepam in dog. J Phann Sci 1974;63:527-32.
9. Hanson RA, Menkes JH. A new anticonvulsant in the management of minor motor seizures. Dev Med Child Neurol 1972;14:3-14.
10. Huang CY, McLeod JG, Sampson D, Hensley WJ. Clonazepam in the treatment of epilepsy. Med J Aust 1974;2:5-8.
11. Dreifuss FE, Penry SK, Rose SW, Kupferberg HJ, Dyken P, Sato S. Serum clonazepam concentrations in children with absence seizures. Neurology 1975;25:255-8.
12. Berlin A, Dahlstrom H. Pharmacokinetics of the anticonvulsant drug clonazepam evaluated from single oral and intravenous doses and by repeated oral administration. Eur J Clin Pharmacol 1975;9:155-9.
13. Jenner P, Chadwick D, Reynolds EH, Marsden CD. Altered 5HT metabolism with clonazepam, diazepam, and diphenylhydantoin. J Pharm Pharmacol 1975;27:707-10.
14. Klotz V, Kangus L, Kanto J. Clinical pharmacokinetics of benzodiazepines. Prog Pharmacol 1980;3:1-71.
15. Miller ME, Garland WA, Min BH, Ludwick BT, Ballard RH, Levy RH. Clonazepam acetylation in fast and slow acetylators. Clin Pharmacol Ther 1981;30:343-7.
16. Elmer GW, Remmel RP. Role of the intestinal microflora in clonazepam metabolism in the rat. Xenobiotica 1984;14:829-40.
17. Jensen PK, Abild K, Ponlsen MN. Serum concentration of clonazepam after rectal administration. Acta Neurol Scand 1983;68:417-20.
18. Mattson H. Current challenges in the treatment of epilepsy. Neurology 1994;44(Suppl 5):S4-9.
19. Nogen AG. The utility of clonazepam in epilepsy of various types. Clin Pediatr 1978;17:71-4.
20. Singh AN, LeMorvan P. Treatment of status epilepticus with intravenous clonazepam. Prog Neuropsychopharmacol Biol Psychiatry 1983; 6:539-42.
21. Lambie DG, Johnson RH. Serum concentration of clonazepam and the therapeutic effect of the drug. Acta Neurol Scand 1983;67:97-102.
22. Suzuki Y, Wang L, Edge J, Mimaki T, Walson PD. Anticonvulsant tolerance to clonazepam in amygdala Kindled rats: Clonazepam concentrations and benzodiazepine receptor binding. Neuropharmacology 1994;33:869-74.
23. Sher PK. Alternate-day clonazepam treatment of intractable seizures. Arch Neurol 1985;42:787-8.
24. Saenz-Lope E, Herranz-Tamarro FJ, Masden JC, Bufil J. Familial photosensitive epilepsy: Effectiveness of clonazepam. Clin Electroencephalogr 1984;15:47-52.
25. Watson P. Clonazepam therapy in reading epilepsy. Neurology 1983; 33:117-8.
26. So EL. Update on epilepsy. Med Clin North Am 1993;77:203-14.
27. Naito A, Wachi M, Nishida M. Clinical effects and plasma concentrations of long-term clonazepam monotherapy in previously untreated epileptics. Acta Neurol Scand 1987;76:58-63.
28. Chee YC, Poh SC. Myoclonus following severe asthma: Clonazepam relieves. Aust N Z J Med 1983;13:285-6.
29. Levy R, Plashe W, Riggs J, Shoulson I. Spinal-myoclonus related to an arteriovenous malformation: Response to clonazepam therapy. Arch Neurol 1983;40:254-5.
30. Wieland C. Facial muscle spasms and clonazepam. Med J Aust 1985; 143:222-3.
31. Stewart JT. Treatment of Huntington's disease with clonazepam. South Med J 1988;81:102.
32. Dulcan MK, Bregman JD, Weller EB, Weller RA. Treatment of childhood and adolescent disorders. In: Schatzberg AF, Nemeroff CB, editors. Textbook of psychopharmacology. Washington, DC: American Psychiatric Press, 1995:669-706.
33. Rasmussen SA, Eisen JL, Pato MT. Current issues in the pharmacologic management of obsessive compulsive disorder. J Clin Psychiatry 1993;54(6 Suppl):4-9.
34. Kaim B. A case of Gilles de la Tourette's syndrome treated with clonazepam. Brain Res Bull 1983;11:213-4.
35. Buckley PF, Meltzer HY. Treatment of schizophrenia. In: Schatzberg AF, Nemeroff CB, editors. Textbook of psychopharmacology. Washington, DC: American Psychiatric Press, 1995:615-39.
36. Feltner DE, Hertzman M. Progress in the treatment of tardive dyskinesia: Theory and practice. Hosp Community Psychiatry 1993;44:25-34.
37. Cohen LS, Rosenbaum JF. Clonazepam: New uses and potential problems. J Clin Psychiatry 1987;48(Suppl 10):S50-5.
38. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1173-8.
39. Koller WC, Herbester G. Adjunct therapy of parkinsonian tremor. Arch Neurol 1987;44:921-3.
40. Comella CL, Klawans HL. Nonparkinsonian movement disorders in the elderly. In: Albert ML, Knoefel JC, editors. Clinical neurology of aging. 2nd ed. New York: Oxford University Press, 1994:502-20.
41. Koller WC, Rosyse VL. Efficacy of primidone in essential tremor. Neurology 1986;36:121-4.
42. Rothwell JC. Orthostatic tremors. In: Quinn NP, Jenner PG, editors. Disorders of movement. London: Academic Press, 1989:521-8.
43. Swerdpow M. Anticonvulsant drugs used in the treatments of lancinating pain: A comparison. Anaesthesia 1981;36:1129-32.
44. Sandyk R. Successful treatment of cerebellar tremor with clonazepam [letter]. Clin Pharmacol 1985;4:615-8.
45. Ancoli-Israel S. Epidemiology of sleep disorders. Clin Geriatr Med 1989;5:347-62.
46. Nofzinger EA, Reynolds CF III. Sleep impairment and daytime sleepiness in later life. Am J Psychiatry 1996;153:941-3.
47. Peled R, Lavie P. Double-blind evaluation of clonazepam on periodic leg movements in sleep. J Neurol Neurosurg Psychiatry 1987; 50:1679-81.
48. Lapierre O, Montplaisir J. Polysomnographic features of REM sleep behavior disorder: Development of a scoring method. Neurology 1992;42:1371-4.
49. Sforza E, Zucconi M, Petronelli R, Lugaresi E, Cirignotta F. REM sleep behavioral disorders. Eur Neurol 1988;28:295-300.
50. Moulin DE, Foley KM, Ebers GC. Pain syndromes in multiple sclerosis. Neurology 1988;38:1830-4.
51. Portenoy RK. Issues in the management of neuropathic pain. In: Basbaum A, Esson JM, editors. Towards a new pharmacotherapy of pain. New York: John Wiley & Sons, 1991:393-410.
52. Bouckoms AJ, Litman RE. Clonazepam in the treatment of neuralgic pain syndrome. Psychosomatics 1985;26:933-6.
53. Currie JN, Matsuo V. The use of clonazepam in the treatment of nystagmus-induced oscillopsia. Ophthalmology 1986;93:924-32.
54. Cox TA. Pupillary escape. Neurology 1992;42:1271-3.
55. Dumermuth G, Kovacs E. The effect of clonazepam (RO5-4023) in the syndrome of infantile spasms with hypsarrhyshmia and in petit mal variant or Lennox syndrome. Acta Neurol Scand Suppl 1973; 49(53):26-8.
56. Court JE, Kase C. Treatment of tic deouloureux with a new anti-convulsant (clonazepam). J Neurol Neurosurg Psychiatry 1976;39: 297-9.
57. Larson AW, Wasserstrom WR, Felsher BF, Chih JC. Post-traumatic epilepsy and acute intermittent porphyria: Effects of phenytoin, carbamazepine, and clonazepam. Neurology 1978;28:824-8.
58. Bonkowsky HL, Sinclair PR, Emery S, Sinclair JF. Seizure management in acute hepatic prophyria: Risks of valproate and clonazepam. Neurology 1980;30:588-92.
59. Veall RM, Hogarth HC. Thrombocytopenia during treatment with clonazepam [letter]. BMJ 1985;4:462.
60. Morselli PL. Anti-epileptic drugs. In: Drug disposition during development. New York: Spectrum, 1977:340-3.
61. Morselli PL. Clinical significance of monitoring plasma levels of benzodiazepine tranquilizers and anti-epileptic drugs. In: Deniker P, editor. Neuropsychopharmacology. Oxford: Pergamon, 1978:877-88.
62. Sullivan FM, McElhatton PR. A comparison of the teratogenic activity of the anti-epileptic drugs carbamazepine, clonazepam, ethosuximide, phenytoin, and primidone in mice. Toxicol Appl Pharmacol 1977;40:365-78.
63. Fisher JB, Edgren BE, Mammel MC, Coleman JM. Neonatal apnea associated with maternal clonazepam therapy: A case report. Obstet Gynecol 1985;66(3 Suppl):34S-35S.